CNS Drugs

, Volume 5, Issue 2, pp 137–146 | Cite as

Benzodiazepine Abuse

Nature and Extent of the Problem
  • J. Roy Robertson
  • Wilfrid Treasure
Adverse Effects

Summary

Benzodiazepines have been available for more than 30 years. At the time of their introduction, these drugs were heralded as a safe alternative to the widely prescribed and addictive barbiturates, and were greeted warmly by the medical profession and by patients. However, the addictive potential of benzodiazepines has been increasingly recognised, placing growing pressure on prescribers and patients to limit their use, especially in the long term.

These precautions seem to have been effective, in that prescribing has decreased and the eruption of problems arising from addiction among patients on prescribed drugs appears to have passed its peak. On the other hand, benzodiazepines have been taken up by street drug abusers, not only at conventional doses and by the oral route, but also in larger doses and intravenously.

Alarming new reports from several continents indicate a serious abuse problem, with major attendant risks in terms of mortality and morbidity in the future. Our understanding of the effects of large doses of benzodiazepines administered by the intravenous or oral route is extremely limited, and further clinical research into the physical, psychological and sociological implications of benzodiazepine abuse needs to be undertaken.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Plant M. What aetiologies? In: Edwards G, Busch C, editors. Drug problems in Britain. A review of ten years. London: Academic Press, 1981: 245–80Google Scholar
  2. 2.
    Turner D. The development of the voluntary sector: no further need for pioneers? In: Strang J, Gossop M. Heroin addiction and drug policy. The British system. Oxford: Oxford Medical Publications, 1994: 223–4Google Scholar
  3. 3.
    The La Roche affair. In: Gossop M. Living with drugs. London: Ashgate, 1993: 53-5Google Scholar
  4. 4.
    Clare AW. Diazepam, alcohol and barbiturate abuse. BMJ 1971; 4: 340PubMedCrossRefGoogle Scholar
  5. 5.
    Hanna SM. A case of oxazepam (Serenid D) dependence. Br J Psychiatry 1972; 120: 443–5PubMedCrossRefGoogle Scholar
  6. 6.
    Misra PC. Nitrazepam (Mogadon) dependence. Br J Psychiatry 1975; 126: 81–2PubMedCrossRefGoogle Scholar
  7. 7.
    Benzodiazepines: use, overuse, misuse, abuse. Lancet 1973 May 19; 1: 1101-2Google Scholar
  8. 8.
    Department of Health and Social Security Advisory Council on the Misuse of Drugs. Treatment and rehabilitation. London: HMSO, 1982Google Scholar
  9. 9.
    Department of Health. Drug misuse and drug dependence: guidelines on clinical management. London: HMSO, 1991Google Scholar
  10. 10.
    Scottish Office Home and Health Department and Scottish Health Services Advisory Council. The management of anxiety and insomnia. A report by the National Medical Advisory Service. Edinburgh: HMSO, 1994Google Scholar
  11. 11.
    Klee_H, Fauzier J, Hayes C, et al. Aids-related risk behaviour, polydrug use and temazepam. Br J Addict 1990; 85: 1125–32PubMedCrossRefGoogle Scholar
  12. 12.
    Ruben SM, Morrison CL. Temazepam misuse in a group of injecting drug users. Br J Addict 1992; 87: 1387–92PubMedCrossRefGoogle Scholar
  13. 13.
    Bond A, Scijas D, Dawling S, et al. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821–30PubMedCrossRefGoogle Scholar
  14. 14.
    Leitner M, Shapland J, Wiles P. Drug usage and drugs prevention: the views and habits of the general public. UK: Home Office (HMSO), 1993Google Scholar
  15. 15.
    King MB. Long-term benzodiazepine users — a mixed bag. Addiction 1994; 89: 1367–70PubMedCrossRefGoogle Scholar
  16. 16.
    Mclnnes E, Powell J. Drug and alcohol referrals: are elderly substance abuse diagnoses and referrals being missed? BMJ 1994; 308: 444–6CrossRefGoogle Scholar
  17. 17.
    Wright N, Caplan R, Payne S. Community survey of long term daytime use of benzodiazepines. BMJ 1994; 309: 27–8PubMedCrossRefGoogle Scholar
  18. 18.
    Wright JD, Pearl L. Knowledge and experience of young people regarding drug misuse, 1969-94. BMJ 1995; 310: 20–4PubMedCrossRefGoogle Scholar
  19. 19.
    Robertson JR, Ronald PJM, Raab GM, et al. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 1994; 309: 369–72PubMedCrossRefGoogle Scholar
  20. 20.
    Ross HE. Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics. Addiction 1993; 88: 209–18PubMedCrossRefGoogle Scholar
  21. 21.
    McDermott P. McDermott’s guide to the depressant drugs. Manchester: Lifeline Publications, 1993Google Scholar
  22. 22.
    Darke S. Benzodiazepine use among injecting drug users: problems and implications. Addiction 1994; 89: 379–82PubMedCrossRefGoogle Scholar
  23. 23.
    Darke S, Ross J, Cohen J. The use of benzodiazepines among regular amphetamine users. Addiction 1994; 89: 1683–90PubMedCrossRefGoogle Scholar
  24. 24.
    Darke S, Hall W, Ross M, et al. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend 1992; 31: 31–6PubMedCrossRefGoogle Scholar
  25. 25.
    Gutierrez-Cebollada J, de la Torre R, Ortuno J, et al. Psychotropic drug consumption and other factors associated with heroin overdose. Drug Alcohol Depend 1994; 35: 169–74PubMedCrossRefGoogle Scholar
  26. 26.
    Robertson JR. Benzodiazepine super-abuse [letter]. Br J Gen Pract 1994; 44(383): 282PubMedGoogle Scholar
  27. 27.
    Golombok S. Causes, effects and treatment of long-term benzodiazepine use: a review of psychological perspectives. Hum Psychopharm 1989; 4: 15–22CrossRefGoogle Scholar
  28. 28.
    Griffith RR, Bigelow GE, Liebson E. Differential effects of diazepam and pentobarbital on mood and behaviour. Arch Gen Psychiatry 1983; 40: 865–73CrossRefGoogle Scholar
  29. 29.
    Strang J, Scivewright N, Farrell M. Intravenous and other novel abuses of benzodiazepines: the opening of Pandora’s box? Br J Addict 1992; 87: 1373–5PubMedCrossRefGoogle Scholar
  30. 30.
    Navaratnam V, Foong K. Opiate dependence — the role of benzodiazepines. Curr Med Res Opin 1990; 11(10): 620–30PubMedCrossRefGoogle Scholar
  31. 31.
    Lader M. Benzodiazepines in profile. Prescr J 1989; 29(1): 12–7Google Scholar
  32. 32.
    King MB. Is there still a role for benzodiazepines in general practice? Br J Gen Pract 1992; 42: 202–5PubMedGoogle Scholar
  33. 33.
    Hudson MMT, Edmonds M, Watkins PJ. Misuse of temazepam [letter]. BMJ 1991; 303: 993PubMedCrossRefGoogle Scholar
  34. 34.
    Maany I, Greenfield H, Dhopesh V, et al. Urinary retention as a possible complication of long-term diazepam abuse. Am J Psychiatry 1948; 5: 685Google Scholar
  35. 35.
    Bergman U, Rosa FW, Baum C. Effects of exposure to benzodiazepine during fetal life. Lancet 1992; 340: 694–6PubMedCrossRefGoogle Scholar
  36. 36.
    Crofts N, Stewart T, Hearne P, et al. Spread of bloodborne viruses among Australian prison entrants. BMJ 1995; 310: 285–8PubMedCrossRefGoogle Scholar
  37. 37.
    Advisory Council on the Misuse of Drugs. Aids and drug misuse report. London: HMSO, 1989Google Scholar
  38. 38.
    Petursson H. The benzodiazepine withdrawal syndrome. Addiction 1994; 89: 1455–9PubMedCrossRefGoogle Scholar
  39. 39.
    Brenner PM, Wolf B, Rechlin T, et al. Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 1991; 29: 195–204PubMedCrossRefGoogle Scholar
  40. 40.
    Brahams D. Medicine and the law. Lancet 1990; 336: 1372–3PubMedCrossRefGoogle Scholar
  41. 41.
    Strang J, Griffiths P, Abbey J, et al. Survey of use of injected benzodiazepines among drug users in Britain. BMJ 1994; 308: 1082PubMedCrossRefGoogle Scholar
  42. 42.
    Des Jarlais DC. Harm reduction — a framework for incorporating science into drug policy. Am J Public Health 1995; 85(1): 10–1PubMedCrossRefGoogle Scholar
  43. 43.
    Ronald PJM, Robertson JR, Wyld R, et al. Heterosexual transmission of HIV in injecting drug users. BMJ 1993; 307: 1184–5PubMedCrossRefGoogle Scholar
  44. 44.
    Hall AJ. Hepatitis B vaccination: protection for how long and against what? Booster injections are not indicated. BMJ 1993; 307: 276–7PubMedCrossRefGoogle Scholar
  45. 45.
    Hindler C, Nazareth I, King M, et al. Drug users’ views on general practitioners. BMJ 1995; 310: 302PubMedCrossRefGoogle Scholar
  46. 46.
    Robertson JR. Treatment for drug dependence [letter]. Lancet 1994; 344: 1640PubMedCrossRefGoogle Scholar
  47. 47.
    Tantam D, Donmall M, Webster A, et al. Do general practitioners and general psychiatrists want to look after drug misusers? Evaluation of a non-specialist treatment policy. Br J Gen Pract 1993; 43: 470–4PubMedGoogle Scholar
  48. 48.
    Gill ON, Noone A, Heptonstall J. Imprisonment, injecting drug use, and bloodborne viruses: a threat of transmission but an opportunity for prevention. BMJ 1995; 310: 275–6PubMedCrossRefGoogle Scholar
  49. 49.
    Christie B. Prison policies put inmates at risk. BMJ 1995; 310: 279CrossRefGoogle Scholar
  50. 50.
    Scivewright N. Benzodiazepine use among injecting drug users [letter]. Addiction 1994; 89: 1701–3CrossRefGoogle Scholar
  51. 51.
    Barnas C, Rossmann M, Roessler H, et al. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992; 12: 397–402PubMedCrossRefGoogle Scholar
  52. 52.
    Darke SG, Ross JE, Hall WD. Benzodiazepine use among injecting heroin users. Med J Aust 1995; 162: 645–7PubMedGoogle Scholar
  53. 53.
    Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990: 10: 237–43PubMedCrossRefGoogle Scholar
  54. 54.
    Gabe J. Promoting benzodiazepine withdrawal. Addiction 1994; 89: 1497–504PubMedCrossRefGoogle Scholar
  55. 55.
    Ashton H. The treatment of benzodiazepine dependence. Addiction 1994; 89: 1535–41PubMedCrossRefGoogle Scholar
  56. 56.
    Darke S. Benzodiazepine use among injecting drug users: reply to Dr. Scivewright [letter]. Addiction 1994; 89: 1703CrossRefGoogle Scholar
  57. 57.
    Lader M. Biological processes in benzodiazepine dependence. Addiction 1994; 89: 1413–8PubMedCrossRefGoogle Scholar
  58. 58.
    Farrell M, Strang J, Needleman J, et al. Policy on drug misuse in Europe. BMJ 1994; 308: 609–10PubMedCrossRefGoogle Scholar
  59. 59.
    New body to fight drugs [news item]. Lancet 1994; 343: 1220Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • J. Roy Robertson
    • 1
  • Wilfrid Treasure
    • 2
  1. 1.Edinburgh Drug Addiction StudyEdinburghScotland
  2. 2.Muirhouse Medical GroupEdinburghScotland

Personalised recommendations